Archive for the ‘Gene Therapy Research’ Category

SILVER SPRING, Md., Jan. 17, 2013 (GLOBE NEWSWIRE) -- Nuvilex, Inc. (NVLX), an international biotechnology company providing natural products and cell and gene therapy solutions for the treatment of human diseases, announced today that its technologies, Cell-in-a-Box(R) and Bac-in-a-Box(R), developed by its subsidiary Austrianova Singapore (ASPL), have been recognized and profiled by the non-profit company, Intellectual Property Intermediary Singapore (IPI Singapore).

The Cell-in-a-Box(R) and Bac-in-a-Box(R) products are proprietary living eukaryotic and bacterial cell encapsulation technological platforms developed by ASPL that can be used for a variety of living cell types. Both of them are unique platform technologies with the potential for such diverse uses as antibody production, treatment of diabetes, part of pancreatic cancer treatment regimen, treatments that employ stem cells, and for the improved use of probiotics, to name a few.

The technologies have been shown to be robust for manipulations and injections and are non-immunogenic. They can be frozen with cells inside that can be recovered years later, and they allow cells to be expanded inside the capsules as mini bioreactors. Moreover, the technology has been shown to be safe and effective for multiple diseases in animal models as well as in human clinical trials for pancreatic cancer.

IPI Singapore was launched in April 2011 as part of the Singapore Research, Innovation, and Enterprise 2015 Plan to contribute to the innovation and enterprise ecosystem in Singapore. IPI's overall aims include helping companies "identify, source, scan and assess technologies" as well as "facilitate technology transfer."

The President and CEO of Nuvilex, Dr. Robert Ryan, stated, "We are pleased IPI Singapore has recognized our technology and will provide access to information about the technologies developed by our ASPL subsidiary. We believe our Company will receive increased exposure to the business and scientific communities due to the recognition by IPI Singapore. Through this recognition and our ongoing efforts, we hope to develop multiple unique products for commercialization from the Cell-in-a-Box(R) and Bac-in-a-Box(R) technology platforms."

About Nuvilex

Nuvilex, Inc. (OTCQB:NVLX) has been a provider of all-natural products for many years and has expanded its company to become an international biotechnology provider of live, therapeutically valuable, encapsulated cells and services for research and medicine. In the biotechnology area of Nuvilex, enhanced antibody production capabilities through encapsulation, our company's offerings will include cancer, diabetes, and other clinical treatments using the company's cell and gene therapy expertise and live-cell encapsulation technology.

The Nuvilex, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=13494

Safe Harbor Statement

This press release contains forward-looking statements described within the 1995 Private Securities Litigation Reform Act involving risks and uncertainties including product demand, market competition, and meeting current or future plans which may cause actual results, events, and performances, expressed or implied, to vary and/or differ from those contemplated or predicted. Investors should study and understand all risks before making an investment decision. Readers are recommended not to place undue reliance on forward-looking statements or information. Nuvilex is not obliged to publicly release revisions to any forward-looking statement, reflect events or circumstances afterward, or disclose unanticipated occurrences, except as required under applicable laws.

View post:
Nuvilex Technologies Recognized by the Singaporean Intellectual Property Intermediary, IPI Singapore

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/8xfhl4/antiviral) has announced the addition of Jain PharmaBiotech's new report "Antiviral Therapeutics - Technologies, Markets and Companies" to their offering.

This report reviews the current state-of-art of antiviral approaches including vaccines, pharmaceuticals and innovative technologies for delivery of therapeutics. The introduction starts with a practical classification of viral diseases according to their commercial importance. Various antiviral approaches are described including pharmaceuticals and molecular biological therapies such as gene therapy and RNA interference (RNAi) as well as vaccines for virus infections. Expert opinion is given about the current problems and needs in antiviral therapy. SWOT (strengths, weaknesses, opportunities and threats) analysis of antiviral approaches is presented against the background of concept of an ideal antiviral agent.

A novel feature of this report is the use of nanotechnology in virology and its potential for antiviral therapeutics. Interaction of nanoparticles with viruses are described. NanoViricides are polymeric micelles, which act as nanomedicines to destroy viruses. Various methods for local as well as systemic delivery of antiviral agents and vaccines are described. Nanobiotechnology plays an important role in improving delivery of antivirals. Advantages and limitations of delivery of gene-based, antisense and RNAi antiviral therapeutics are discussed.

Markets for antivirals are considered according to viruses and diseases caused by them and also according to management approaches: antiviral drugs, vaccines, MAbs and innovative approaches that include immunological and use of other technologies such as gene therapy, antisense, RNAi and nanobiotechnology. Antiviral markets are estimated starting with 2012 with projections up to the year 2022.

Profiles of 178 companies that are involved in developing various technologies and products are profiled and with 167 collaborations. These include major pharmaceutical companies (13), Biopharmaceutical companies with antiviral products (80), Antiviral drug companies (25) as well as viral vaccine companies (60). The report is supplemented with 50 tables, 11 figures and 470 references from the literature.

Key Topics Covered:

Executive Summary

1. Introduction to Virology

2. Antiviral Approaches

Read the original here:
Research and Markets: Antiviral Therapeutics - Technologies, Markets and Companies - 2013

Jews of European origin are a mix of ancestries, with many hailing from tribes in the Caucasus who converted to Judaism and created an empire that lasted half a millennium, according to a gene study.

The investigation, its author says, should settle a debate that has been roiling for more than two centuries.

Jews of European descent, often called Ashkenazis, account for some 90 percent of the more than 13 million Jews in the world today.

According to the so-called Rhineland Hypothesis, Ashkenazis descended from Jews who progressively fled Palestine after the Moslem conquest of 638 AD.

They settled in southern Europe and then, in the late Middle Ages, about 50,000 of them moved from the Rhineland in Germany into eastern Europe, according to the hypothesis.

But detractors say this idea is implausible.

Barring a miracle --which some supporters of the Rhineland Hypothesis have in fact suggested -- the scenario would have been demographically impossible.

It would mean that the population of Eastern European Jews leapt from 50,000 in the 15th century to around eight million at the start of the 20th century.

That birth rate would have been 10 times greater than that of the local non-Jewish population. And it would have occurred despite economic hardship, disease, wars and pogroms that ravaged Jewish communities.

Seeking new light in the argument, a study published in the British journal Genome Biology and Evolution, compares the genomes of 1,287 unrelated individuals who hail from eight Jewish and 74 non-Jewish populations.

Continue reading here:
Gene study settles debate over origin of European Jews

People who have a certain variant of the ABCC11 gene don't produce under arm odor, though many of them still wear deodorant, Bristol University researchers report in the Journal of Investigative Dermatology. (The variant is also linked to dry earwax.)

Drawing on about 17,000 people from the Avon Longitudinal Study of Parents and Children study, the researchers investigate how having the ABCC11 rs17822931 variant affects people's hygiene behavior. People who are homozygotes for the rs17822931 A allele are five times less likely to use deodorant than GG homozygotes and heterozygotes are, they find.

However, the researchers note that nearly 80 percent of white European mothers in the study who, based on their genotype, should not produce under arm odor still wear deodorant and that that behavior is likely socially and culturally driven.

"This effect has a biological basis that can result in a change in the family's environment if an aerosol deodorant is used. It also indicates potential cost saving to the nonodorous and scope for personalized genetics usage in personal hygiene choices, with consequent reduction of inappropriate chemical exposures for some," the researchers add.

Read the original here:
The Deodorant Gene …

PARK CITY, Utah--(BUSINESS WIRE)--

Rejuvenation Labs today announced the launch of Resvology, the only topical anti-aging skin care line containing the multi-patented, gene-activating 4-AR Molecule, a uniquely stabilized ester form of the widely recognized youth molecule resveratrol.

Resvologys anti-aging effectiveness is based upon a proprietary molecule discovered by a team of cancer researchers at Brigham Young University working under a grant by the National Institutes of Health. Through in-vitro studies, the 4-AR Molecule (or resveratryl acetate) has been observed to activate 85 key skinrelated genes to fuel gene activity, including:

Unveiled at the Sundance Film Festival, the Resvology Age Corrective collection consists of three core products designed for all skin types: the Age Corrective Wrinkle Treatment, Age Corrective Eye Cream and the Gentle Cleansing Gel. These products work together to hydrate and smooth skin texture and reduce signs of aging, helping keep skin looking firm, lifted and youthful.

Researchers also observed a significant correlation between the 4-AR Molecule in higher production of several proteins and enzymes important to cell regeneration. In clinical trials, consumers have reported that Resvology hydrated skin, removed fine lines and wrinkles, and minimized puffiness and dark circles around the eyes.

The discovery of the 4-AR Molecule has improved our understanding of the skins aging process, and how it can look and feel more youthful, said Kevin Passey, CEO of Rejuvenation Labs. Resvology sets a new standard for anti-aging effectiveness in the skin care industry by creating the most stable and accessible use of resveratrol. Resvology will make a genuine difference in how women look and feel.

The science behind the 4-AR Molecule captured the early attention of entrepreneurs Gary Crocker and Dinesh Patel, two leading life science experts who have each founded numerous successful biotechnology companies. Crocker and Patel are members of the board of directors of Rejuvenation Labs, and together they are providing substantial financial backing for the launch of Resvology.

Crocker has founded multiple successful medical device companies, including Research Medical, which became the worlds largest supplier of cardiac bypass catheters before it was acquired by Baxter International for $250 million. Crocker is currently chairman of Merrimack Pharmaceuticals, a leader in oncology research and treatment, and CEO of Crocker Ventures. Patel, one of the leading fathers of biotechnology in the Mountain West region, has led or helped launch many companies. Holder of numerous patents, Patel was also CEO of Theratech, a leader in drug delivery technology that he co-founded with Crocker. Theratech was purchased by Watson Pharmaceuticals.

It is exciting to be part of a team of scientists and business leaders that are creating an innovative skin care line with observable results, said Crocker. The discovery of the 4-AR Molecule and the quality of the scientific and business teams made it clear that this is more than just another skin care line. Rejuvenation Labs will make a major impact in the beauty care market.

Resvology will roll out in the first quarter of 2013 and be sold at specialty retailers. For more information, visit http://www.resvology.com.

Originally posted here:
Resvology Launches Anti-Aging Skin Care Line with Patented Gene-Activating Molecule

Editor's Choice Academic Journal Main Category: Autism Also Included In: Genetics Article Date: 16 Jan 2013 - 12:00 PST

Current ratings for: New Gene Variants Linked To Autism Discovered

2 (1 votes)

The research team, led by Hakon Hakonarson, MD, PhD, explained in the journal PLOS ONE that they identified 25 additional copy number variants (CNVs) that occur in some people with autism. CNVs are duplicate or missing stretches of DNA.

They describe these copy number variants as individually rare, but of "high impact", meaning that each one has a strong effect in increasing a person's risk for autism.

Dr. Hakonarson said:

Scientists from the Seaver Autism Center at Icahn School of Medicine at Mount Sinai said that there are hundreds of mutated genes linked to ASDs.

In this study, the team initially analyzed the DNA of 55 people from families in Utah with multiple members who had been diagnosed with ASDs. The data from high-risk families had been collected by Mark Leppert, PhD. They identified 153 CNVs as potentially linked to autism.

The team wanted to look at these CNVs in a broader ASD population. They custom-designed a DNA array with probes for all 153 CNVs, as well as an additional 185 CNVs which had been linked to autism in previous studies. They gathered and examined all the data to determine how common all the CNVs were in 3,000 people with an ASD and 6,000 control subjects previously gathered in studies carried out at The Children's Hospital of Philadelphia.

The researchers found that:

Read the original:
New Gene Variants Linked To Autism Discovered

Newswise Melanomas that develop in the eye often are fatal. Now, scientists at Washington University School of Medicine in St. Louis report they have identified a mutated gene in melanoma tumors of the eye that appears to predict a good outcome.

The research is published in the advance online edition of Nature Genetics.

We found mutations in a gene called SF3B1, says senior author Anne Bowcock, PhD, professor of genetics. The good news is that these mutations develop in a distinct subtype of melanomas in the eye that are unlikely to spread and become deadly.

Eye tumors called uveal melanomas occur in about 2,000 patients a year, making up about 5 percent of all melanomas. In many patients, there are no symptoms, and the tumors become fatal when they spread to the liver.

Several years ago, Bowcock and the studys lead author, J. William Harbour, MD, a former Washington University eye surgeon who is now at the University of Miami, identified a commonly mutated gene, BAP1, in patients with uveal melanomas.

They found BAP1 alterations in about 80 percent of uveal melanomas with a poor prognosis, called class II tumors. About 75 percent of patients with these tumors die within five years, a sharp contrast to the generally favorable outcomes of patients whose tumors dont have BAP1 mutations, called class I.

For the new study, Bowcock and her colleagues initially sequenced the DNA of uveal melanomas from 18 patients whose BAP1 status was already known. Seven had no BAP1 mutations (class I tumors), and 11 had BAP1 mutations (class II tumors).

The researchers analysis uncovered alterations in the SF3B1 gene in three of the patients.

This is the first time mutations in this gene have been found in uveal melanoma, says Bowcock, who also is a professor of pediatrics and of medicine.

As part of the current study, the researchers also looked for SF3B1 mutations in uveal melanoma tumors from 102 patients, finding it in nearly 20 percent of them. Mutations in the gene were linked to favorable features, including a younger age at diagnosis and a far lower metastasis rate.

Continued here:
Gene in Eye Melanomas Linked to Good Prognosis

Public release date: 17-Jan-2013 [ | E-mail | Share ]

Contact: Matt Fearer fearer@wi.mit.edu 617-452-4630 Whitehead Institute for Biomedical Research

CAMBRIDGE, Mass. (January 17, 2013) Using only a computer, an Internet connection, and publicly accessible online resources, a team of Whitehead Institute researchers has been able to identify nearly 50 individuals who had submitted personal genetic material as participants in genomic studies.

Intent on conducting an exercise in vulnerability researcha common practice in the field of information securitythe team took a multi-step approach to prove that under certain circumstances, the full names and identities of genomic research participants can be determined, even when their genetic information is held in databases in de-identified form.

This is an important result that points out the potential for breaches of privacy in genomics studies, says Whitehead Fellow Yaniv Erlich, who led the research team. A description of the groups work is published in this weeks Science magazine.

Erlich and colleagues began by analyzing unique genetic markers known as short tandem repeats on the Y chromosomes (Y-STRs) of men whose genetic material was collected by the Center for the Study of Human Polymorphisms (CEPH) and whose genomes were sequenced and made publicly available as part of the 1000 Genomes Project. Because the Y chromosome is transmitted from father to son, as are family surnames, there is a strong correlation between surnames and the DNA on the Y chromosome.

Recognizing this correlation, genealogists and genetic genealogy companies have established publicly accessible databases that house Y-STR data by surname. In a process known as surname inference, the Erlich team was able to discover the family names of the men by submitting their Y-STRs to these databases. With surnames in hand, the team queried other information sources, including Internet record search engines, obituaries, genealogical websites, and public demographic data from the National Institute of General Medical Sciences (NIGMS) Human Genetic Cell Repository at New Jerseys Coriell Institute, to identify nearly 50 men and women in the United States who were CEPH participants.

Previous studies have contemplated the possibility of genetic identification by matching the DNA of a single person, assuming the persons DNA were cataloged in two separate databases. This work, however, exploits data between distant paternally-related individuals. As a result, the team notes that the posting of genetic data from a single individual can reveal deep genealogical ties and lead to the identification of a distantly-related person who may have no acquaintance with the person who released that genetic data.

We show that if, for example, your Uncle Dave submitted his DNA to a genetic genealogy database, you could be identified, says Melissa Gymrek, a member of the Erlich lab and first author of the Science paper. In fact, even your fourth cousin Patrick, whom youve never met, could identify you if his DNA is in the database, as long as he is paternally related to you.

Aware of the sensitivity of his work, Erlich emphasizes that he has no intention of revealing the names of those identified, nor does he wish to see public sharing of genetic information curtailed.

More here:
Scientists expose new vulnerabilities in the security of personal genetic information

CHICAGO, Jan. 17, 2013 (GLOBE NEWSWIRE) -- The American Medical Association (AMA) announced an agreement with the National Library of Medicine that will enhance the National Institutes of Health's Genetic Testing Registry, a centralized public source for information on genetic tests.

Under the agreement, Current Procedural Terminology (CPT(R)) codes for molecular pathology tests will be integrated into the publicly available Genetic Testing Registry (GTR), which is managed by the National Center for Biotechnology Information, a division of the National Library of Medicine at NIH. The AMA-created CPT codes describe the latest advances in genetic testing and molecular diagnostic services for reporting and tracking purposes.

"Incorporating these CPT codes into GTR will help clinicians pinpoint practical information about genetics in a centralized resource," said GTR Director Wendy Rubinstein, M.D., Ph.D.

"CPT codes are a critical element to building an infrastructure that supports moving new genetic discoveries to the front lines of clinical care as we move into an era of personalized medicine," said AMA President Jeremy A. Lazarus, M.D. "Adding a CPT coding reference to the Genetic Testing Registry gives physicians an invaluable information source that will enhance the reporting of genetic tests and services."

The AMA has been involved with coding solutions for molecular pathology services since 1998. New, more detailed CPT codes for molecular pathology became effective in 2012 to capture and describe the latest scientific advances in this rapidly expanding field of medicine. The ongoing process has so far created more than 100 codes for reporting innovative diagnostic services, and advances the AMA's overarching goal of reducing disease burdens, improving health outcomes and reducing long-term care costs.

Media Contact: Robert J. Mills AMA Media Relations (312) 464-5970 robert.mills@ama-assn.org

About the American Medical Association (AMA)

The American Medical Association helps doctors help patients by uniting physicians nationwide to work on the most important professional, public health and health policy issues. The nation's largest physician organization plays a leading role in shaping the future of medicine. For more information on the AMA, please visit http://www.ama-assn.org.

This information was brought to you by Cision http://www.cisionwire.com http://www.cisionwire.com/american-medical-association/r/ama-enhances-genetic-testing-registry,c9358492

Continued here:
AMA Enhances Genetic Testing Registry

The Week at Duke {in 60 Seconds}: Gun Debate; MLK Address; Bryan Center
Duke University juniors Danny Nolan and Emily Sobel deliver a week #39;s worth of campus news in a minute. Duke faculty and students have been weighing in on the national debate about gun policy. One prominent voice in the debate is public policy professor Phil Cook. "I think we are at a point now that is much like we were in the 1980s with drunk driving," Cook said. "MADD and other organizations worked hard to get judges to treat that as a serious crime and I think now we have to make sure that the judges take illegal carrying of guns as a serious crime." A new study led by Duke doctor Barton Haynes helps scientists better understand how an experimental HIV vaccine works -- and where it fails. The keynote address at Duke #39;s Martin Luther King Junior celebration January 20 will be given by Duke Divinity School professor, the reverend William Turner. Biology professor Mohamed Noor is teaching a free online course on evolution and genetics on the Coursera platform. The Bryan Center is getting a makeover. It will eventually look like this. For more Duke news everyday, visit Duke Today at today.duke.edu.

By: Duke

More:
The Week at Duke {in 60 Seconds}: Gun Debate; MLK Address; Bryan Center - Video

I feel for u
Just hear her out an think on your time to know an see what your brain DNA genetics produce? Brain gene activity changes through life Body Brain.

By: Woweetime Morecolor

Read the rest here:
I feel for u - Video

J Love Natural Hair Care
J Love maker of Genetics, Progenics, Variations, professional hair care systems I created this video with the YouTube Video Editor (www.youtube.com

By: Joseph Love

See the article here:
J Love Natural Hair Care - Video

The Hidden Source Episode 36 -RQ RQ RQ THEY ALL SUCK-
Myself ThatOneRebel playing some The Hidden Source! Nobody can see The Hidden only trained eyes can see him well! WATCH AS I MURDER EVERYONE AS THE HIDDEN MAHAAAHAHAHA The objective of The Hidden Source is that the humans aka IRIS must eliminate The Hidden to win vice versa for the Hidden but as the title says he is invisible and only is equipped with a knife capable of a one hit kill depending on server and only three grenades. The hidden has many abilities like taunting, super strength to ram objects into IRIS soldiers or be able to leap super high and hang on buildings. Lastly The Hidden can heal himself by eating bodies but only if they are stabbed to death not PIGSTICKED! (which is the one hit kill move) The IRIS are equipped with four weapons ranging from shotgun to rifle to SMG and a few options of equipment like senors to laser optics on your gun. Game is The Hidden Source which requires Half life 2 engine meaning you have to have Half Life 2 purchased already or another source game to run with STORYLINE In the early 1950s human genetics experimentation was taking its first, tentative steps. Amongst many other black projects, a team of British scientists working at an Infinitum Research experimental station stumbled across some remarkable phenomena involving DNA manipulation. This led to deeper research with dangerously unpredictable results, often leading to human patients losing their lives in irresponsible and immoral experiments. Time passed on, and by the mid ...

By: ThatOneRebel55

Read more:
The Hidden Source Episode 36 -RQ RQ RQ THEY ALL SUCK- - Video

Genetics Intro - Who is Gregor Mendel?
This video is an introduction to Genetics and Gregor Mendel. The video concludes with a discussion on Genotypes and Phenotypes

By: Charles Filipek

Originally posted here:
Genetics Intro - Who is Gregor Mendel? - Video

#1 How to Train and Build Biceps. Hints and Tips. Bulking Up
How to Train and Build Biceps. Hints and Tips. Bulking Up Yurii Spasokukotskyi, a personal trainer and bodybuilding champion came into the sport in 1994. Initialy he used to have narrow shoulders, weak muscles and a big fat belly. But even after 7 years of regular gym training 3-4 times a week didn #39;t bring hime good results. The reason was that regular and hard workout vs bad genetics was not cool enough without a competent training system. Then Yurii has developed his own system which works 100% and may ba suitable for everybody. And he himself got much greater results in bodybuilding during that one year than during those 7 years of training before. Now all people, who want to get a significant progress in bodybuilding and fitness are getting success with Yurii. He gives personal trainings in Skype and has thousands of happy clients around the world. Build muscle really fast: biceps.com.ua In today #39;s episode, it #39;s time to build some MONSTER BICEPS! I #39;ve gotten a lot of questions lately in the comments about what I do for my arms, and how to develop a big biceps . In this video I #39;m going to show you two of the exact exercises I use to get big arms myself. Building a biceps "peak" will make a HUGE difference in how big your biceps appear. If they #39;re shaped right, your biceps will appear much bigger than someone whose are the same size, but whose biceps do not have a dramatic peak. Developing your bracs (muscles outside your biceps) with the other exercise I show in this ...

By: WorkoutTV24

Read the original:
#1 How to Train and Build Biceps. Hints and Tips. Bulking Up - Video

#2 Pretty girls don #39;t like strong men. Joke
Pretty girls don #39;t like strong men. Joke Yurii Spasokukotskyi, a personal trainer and bodybuilding champion came into the sport in 1994. Initialy he used to have narrow shoulders, weak muscles and a big fat belly. But even after 7 years of regular gym training 3-4 times a week didn #39;t bring hime good results. The reason was that regular and hard workout vs bad genetics was not cool enough without a competent training system. Then Yurii has developed his own system which works 100% and may ba suitable for everybody. And he himself got much greater results in bodybuilding during that one year than during those 7 years of training before. Now all people, who want to get a significant progress in bodybuilding and fitness are getting success with Yurii. He gives personal trainings in Skype and has thousands of happy clients around the world. Build muscle really fast: biceps.com.ua In today #39;s episode, it #39;s time to build some MONSTER BICEPS! I #39;ve gotten a lot of questions lately in the comments about what I do for my arms, and how to develop a big biceps . In this video I #39;m going to show you two of the exact exercises I use to get big arms myself. Building a biceps "peak" will make a HUGE difference in how big your biceps appear. If they #39;re shaped right, your biceps will appear much bigger than someone whose are the same size, but whose biceps do not have a dramatic peak. Developing your bracs (muscles outside your biceps) with the other exercise I show in this video will also ...

By: WorkoutTV24

Continue reading here:
#2 Pretty girls don't like strong men. Joke - Video

Thalassaemia - Introduction, Classification, Clinical Features, Diagnosis, Treatment Complications
A brief video to refresh the memories of my busy students with a dose of pathology ! Recording took only half an hour, editing 5 minutes - But uploading was taking for ever ... Hope some one finds this helpful ... peace Tags : Thalassemia, Definition, Classification, Role of Genetics in Thalassemia, Pathophysiology of Alpha and Beta Thalassemia, Clinical Features, Main Findings in Blood Picture, Target Cells, How and why Target Cells Formed in Thalassemia, Role of Parvo virus B19 in thalassemia, Treatment and complications.

By: Rabiul Haque

Link:
Thalassaemia - Introduction, Classification, Clinical Features, Diagnosis, Treatment

#4 Shoulder Dumbell Fly, one arm style. My own Shoulder Workout
Shoulder Dumbell Fly, one arm style. My own Shoulder Workout Yurii Spasokukotskyi, a personal trainer and bodybuilding champion came into the sport in 1994. Initialy he used to have narrow shoulders, weak muscles and a big fat belly. But even after 7 years of regular gym training 3-4 times a week didn #39;t bring hime good results. The reason was that regular and hard workout vs bad genetics was not cool enough without a competent training system. Then Yurii has developed his own system which works 100% and may ba suitable for everybody. And he himself got much greater results in bodybuilding during that one year than during those 7 years of training before. Now all people, who want to get a significant progress in bodybuilding and fitness are getting success with Yurii. He gives personal trainings in Skype and has thousands of happy clients around the world. Build muscle really fast: biceps.com.ua In today #39;s episode, it #39;s time to build some MONSTER BICEPS! I #39;ve gotten a lot of questions lately in the comments about what I do for my arms, and how to develop a big biceps . In this video I #39;m going to show you two of the exact exercises I use to get big arms myself. Building a biceps "peak" will make a HUGE difference in how big your biceps appear. If they #39;re shaped right, your biceps will appear much bigger than someone whose are the same size, but whose biceps do not have a dramatic peak. Developing your bracs (muscles outside your biceps) with the other exercise I show in ...

By: WorkoutTV24

See the article here:
#4 Shoulder Dumbell Fly, one arm style. My own Shoulder Workout - Video

Synastry - Cryolife
A song from an awesome band from new album Our Memetic Imprints, download or buy it from here synastry.bandcamp.com Song will be removed at the request of the author as I do not own it and this video is for promotional purposes of an awesome band. Jimmy Anastasopoulos - Vocals Pavel Ikonomov - Guitars Garen Vartivarian - Bass Kegham Kesserian - Drums All Music by Synastry All Lyrics by Jimmy Anastasopoulos Drums, Guitars and Bass Recorded by JF Dagenais Vocals Recorded by Chris Donaldson Mixed by JF Dagenais Samples production by Kevin Jardine Mastering by Jef Fortin GUITAR SOLO on Negative Genetics by Chris Donaldson. LEAD GUITAR OUTRO on Negative Genetics by JF Dagenais. Artwork by Mikio Murakami @ SILENT Q Design.

By: Necromael21

See more here:
Synastry - Cryolife - Video

J-Don - Bad Odour
J-Don with his reply to Emre Lyrics: [Chorus] Oh Oh sometimes I smell a bad odour, yeah I smell an odour that i #39;ve never never never never smelt before no no i smell a bad odour, yeah Oh Oh sometimes I smell a bad odour, yeah I smell an odour that i #39;ve never never never never smelt before no no i smell a bad odour, yeah Why you sending back and foreskin me to do this I #39;m going to crucify your ass so you can call me Judas I #39;m gonna sharpen up my act cause before my bars were useless standing harmless with an axe pretending to be ruthless stealing my chromosome bar was kind of pathetic lets forget the racism and skip to genetics your mom gives head for bus fare and gets the camel home at least I know no why you #39;ve got down syndrome you follow me around school constantly lurking your skin complexion reminds me of a greasy gherkin your dads a sikh he wears a turban you write crap bars and you think your urban [Chorus] Oh Oh sometimes I smell a bad odour, yeah I smell an odour that i #39;ve never never never never smelt before no no i smell a bad odour, yeah Oh Oh sometimes I smell a bad odour, yeah I smell an odour that i #39;ve never never never never smelt before no no i smell a bad odour, I don #39;t know why I knocked on your door anymore considering I have a key I bet if I opened the door you mom would be waiting for me flicking her bean so vigorously in perfect syncronicity to the theme tune of sesame street flicking it so hard an vigorous, told her not to be so brave and shiverous ...

By: Rap Battles

Go here to read the rest:
J-Don - Bad Odour - Video

#10 Results before and after. A 50 years old man loses 31 kilo! Diet plus fitness
Results before and after. A 50 years old man loses 31 kilo! Diet plus fitness Yurii Spasokukotskyi, a personal trainer and bodybuilding champion came into the sport in 1994. Initialy he used to have narrow shoulders, weak muscles and a big fat belly. But even after 7 years of regular gym training 3-4 times a week didn #39;t bring hime good results. The reason was that regular and hard workout vs bad genetics was not cool enough without a competent training system. Then Yurii has developed his own system which works 100% and may ba suitable for everybody. And he himself got much greater results in bodybuilding during that one year than during those 7 years of training before. Now all people, who want to get a significant progress in bodybuilding and fitness are getting success with Yurii. He gives personal trainings in Skype and has thousands of happy clients around the world. Build muscle really fast: biceps.com.ua In today #39;s episode, it #39;s time to build some MONSTER BICEPS! I #39;ve gotten a lot of questions lately in the comments about what I do for my arms, and how to develop a big biceps . In this video I #39;m going to show you two of the exact exercises I use to get big arms myself. Building a biceps "peak" will make a HUGE difference in how big your biceps appear. If they #39;re shaped right, your biceps will appear much bigger than someone whose are the same size, but whose biceps do not have a dramatic peak. Developing your bracs (muscles outside your biceps) with the other ...

By: WorkoutTV24

Read the original:
#10 Results before and after. A 50 years old man loses 31 kilo! Diet plus fitness - Video

SEATTLE, WA--(Marketwire - Jan 17, 2013) - Atossa Genetics, Inc. ( NASDAQ : ATOS ) announced today that Steven C. Quay, M.D., Ph.D., FCAP, Chairman, CEO and President of Atossa, will make two presentations at the Personalized Medicine World Conference (PWMC) being held at the Computer History Museum in Mountain View, California, on January 28th and 29th, 2013. Dr. Quay will discuss a strategy for providing care to patients at every stage of a disease or condition, and how it may be possible to actually prevent breast cancer.

Here are summaries of his two presentations:

The "CarePath" Business Model in Personalized Medicine - 9:45 am Pacific Time, Jan. 28, 2013

Abstract: Medical practice is moving toward treatments that are based on simple protocols. For example, if a woman has a lump in her breast, she typically gets a standard biopsy. These so-called protocol-driven treatment paradigms thus make it hard for genomics-based diagnostic companies to launch innovative tests that may offer better care but which don't fit the established protocol. There is another possible approach, however -- designing a suite of tests and procedures that work together to help patients at every stage of a disease or condition. Atossa Genetics calls this the 'CarePath' business model, and believes it offers an insightful way to distinguish a truly innovative company from the crowd, to better treat a medical condition by establishing synergies across all parts of the business, and to build stakeholder value for the organization. Atossa Genetics has created such a CarePath for breast health with eleven FDA-cleared medical devices, four CLIA-validated Laboratory Developed Tests, and a planned pharmaceutical/biotech treatment program.

Breast Cancer Prevention through Diagnosis and Treatment - 4:15 pm Pacific Time, Jan. 28, 2013

Abstract: Dr. Quay will discuss how to obtain routine, repeated, painless breast biopsy samples non-invasively for cytopathology, next-generation sequencing, proteome, and transcriptome analysis of precursors to breast cancer. This approach makes it possible to identify the earliest "-omic" changes in reversible precursor lesions of the breast, such as atypical ductal hyperplasia. The test not only provides more accurate assessments of patients' risks of future breast cancer, it also offers a source of breast specimens for potential use in biomarker discovery, clinical trial support and patient selection. And most importantly, it opens the door to ultimately preventing breast cancer through the treatment of reversible hyperplastic lesions within the breast ducts.

"Our personalized medicine approach to breast health represents a new paradigm in the way we think about and approach breast cancer and breast cancer prevention," stated Dr. Quay. "I appreciate the opportunity to make two presentations at this important conference, which brings together thought leaders from many prestigious institutions, including Stanford University, Harvard University and other world-renowned institutions."

About Atossa Genetics, Inc.

Atossa Genetics, Inc. ( NASDAQ : ATOS ), The Breast Health Company, is based in Seattle, Washington, and is focused on preventing breast cancer through the commercialization of patented, FDA-cleared diagnostic medical devices and patented, laboratory developed tests (LDT) that can detect precursors to breast cancer up to eight years before mammography, and through research and development that will permit it to commercialize treatments for pre-cancerous lesions.

The National Reference Laboratory for Breast Health (NRLBH), a wholly owned subsidiary of Atossa Genetics, Inc., is a CLIA-certified high-complexity molecular diagnostic laboratory located in Seattle, Washington, that provides the patented ForeCYTE Breast Health Test, a risk assessment test for women 18 to 73 years of age akin to the Pap smear, and the ArgusCYTE Breast Health Test, a blood test for recurrence in breast cancer survivors that provides a "liquid biopsy" for circulating cancer cells and a tailored treatment plan for patients and their caregivers.

See the article here:
Atossa Genetics, Inc. to Present at the Personalized Medicine World Conference in Mountain View, California

An Australian researcher has developed a gene therapy for HIV - which has the potential to stop the virus from turning deadly.

David Harrich, an associate professor at the Queensland Institute of Medical Research (QIMR), will begin animal trials this year, but experiments in humans are still five years away.

Harrich has manipulated an HIV protein involved in gene expression, known as Tat, and turned it into a weapon against the virus.Using human immune system cells, known as T-cells, in the laboratory, he's shown the mutant protein prevents HIV replication.

At the same time, Harrich said the modified protein, dubbed Nullbasic, did not appear to adversely affect the human cells.

"So far we haven't found that Nullbasic causes toxicity in the cells we've tested," he said.

"I'm excited. Every test I've done with this agent has succeeded. It makes me optimistic it will work in humans. At the same time, I'm a skeptical scientist, and I'm going to require proof it can jump every hurdle."

QIMR researchers will soon begin testing the protein in mice.

"Before you can trial it on humans, it's going to have to go through rigorous testing in animals for safety," Harrich said.

In order for human cells to make the HIV-inhibitory protein in the laboratory, Harrich had to insert a new gene - a process known as gene therapy.

He said the idea of gene therapy being used as a treatment for HIV had gained momentum since the case of a man known as the Berlin Patient, considered by doctors to have been cured of the virus.

The rest is here:
Australian researcher may have developed the cure for AIDS

MFIII Swiss Cell Therapy for Regeneration, Rejuvenation and Revitalisation
MFIII Swiss Cell Therapy for Regeneration, Rejuvenation and Revitalisation

By: Vina Higgs

Read the original post:
MFIII Swiss Cell Therapy for Regeneration, Rejuvenation and Revitalisation - Video

ALLENDALE, N.J. and OXFORD, United Kingdom, Jan. 16, 2013 (GLOBE NEWSWIRE) -- NeoStem, Inc. (NYSE MKT:NBS) and its subsidiary, Progenitor Cell Therapy LLC ("PCT"), together with Adaptimmune Limited and Adaptimmune LLC (collectively, "Adaptimmune"), announced today a Services Agreement under which PCT will provide services to support Adaptimmune's NYESO-1c259-T cell therapy product being developed for multiple oncology indications (for more information with respect to Adaptimmune's clinical trials, see clinicaltrials.gov, identifiers NCT01350401, NCT01343043 and NCT01352286).

PCT's services will include the transfer and qualification of Adaptimmune's manufacturing process for its NYESO-1c259-T cell therapy product candidate at PCT's facility in Allendale, New Jersey and subsequent manufacturing of the product for Adaptimmune's clinical trials.

Adaptimmune develops products containing unique engineered T cell receptors for the treatment of cancer and infectious diseases. The company has a research base in Oxford, UK and a clinical base in Philadelphia, Pennsylvania.

In December, at the American Society of Hematology conference, Adaptimmune announced encouraging preliminary results from its expanded multiple myeloma trial. Related trials in melanoma and sarcoma are also recruiting patients.

PCT is an internationally recognized contract development and manufacturing organization with facilities in Allendale, New Jersey and Mountain View, California. The company has expertise in GMP manufacture for cell therapies, including dendritic cells, stem cells and T cells. Notably, PCT provided manufacturing for the pivotal studies for Dendreon's Provenge(R), the first cell therapy approved for cancer treatment.

"With our sights set on future pivotal trials for our T cell therapy products, we have invested significant effort towards establishing capabilities within Adaptimmune that support expansion of our clinical platform in terms of both scale and compliance with FDA requirements beyond phase I/II. Our relationship with PCT is an important component," said James Noble, Chief Executive Officer of Adaptimmune. "PCT's impressive level of experience in the burgeoning field of cell therapy, combined with their flexible capacity and professionalism, are among the reasons we selected them for this critical role for our T cell product."

"We are excited to enter into this agreement with Adaptimmune, an innovator for T cell therapy to treat cancers," said Robert A. Preti, PhD, President and Chief Scientific Officer of PCT. "Given our extensive experience with technology transfer, process qualification and GMP manufacturing, we feel PCT will be an asset to Adaptimmune as it develops its product for the U.S. commercial market."

Dr. Robin L. Smith, NeoStem's Chairman and Chief Executive Officer, stated that, "PCT's expertise is recognized globally as demonstrated by the services agreement executed with Adaptimmune. As PCT continues to expand its GMP manufacturing capabilities and focus to support the development of an increasingly wide range of cell therapies under development, it remains focused on providing outstanding client services."

About Adaptimmune

Adaptimmune focuses on the use of T cell therapy to treat cancer and infectious disease. It aims to use the body's own machinery -- the T cell -- to target and destroy cancerous or infected cells.

Read more here:
NeoStem's Subsidiary, Progenitor Cell Therapy, Enters Into a Cell Therapy Manufacturing Services Agreement With ...